Skip to main content
Caplight Logo









MFX

MFX

Private
StevenageHealthcare & Life Scienceshttps://mfx.bio/

Last Round

Grant

Nov 19, 2025

Total Funding Raised

$2.61M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

MFX is a biotechnology company that provides a scalable bioreactor and data platform for cell and gene therapy research, development, and manufacturing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

bioprocessingcell and gene therapyCGTbioreactorbiotech manufacturinglab automationmicrofluidicsprocess developmentCDMObio-manufacturingbiotech hardwarebioprocess analyticsautologous therapyallogeneic therapybiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MFX Comparables

Compare MFX with similar companies based on industry and business-model similarity.

MFX comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ori Biotech
88%
Aglaris
87%
Adva Biotechnology
87%

MFX Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 19, 2025
GrantDec 19, 2023
VC RoundDec 8, 2022
SeedApr 20, 2020

Key People

Founding team and executive leadership

Steve Gore

Chief Financial Officer

Executive Team

MFX Investors

Notable investors and investment history

MFX investors
InvestorRounds
Innovate UKGrant
Cambridge AngelsSeed
UK Innovation & Science Seed FundVC Round, Seed
Perscitus LLPVC Round
88 Capital & InvestmentsSeed
Puffin PointVC Round
Longwall Venture PartnersVC Round, Grant, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 19, 2025

    Received grant funding.

  • Mar 17, 2025

    Dr. Katy Newton appointed to lead innovation in cell-based therapies.

MFX Filings

Explore SEC and related filing metadata, where available.

MFX filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MFX's valuation, stock price, and market status.

Is MFX a public or private company?

MFX is a private company.

What is the current stock price of MFX?

MFX is a private company with no public stock price. No recent secondary market data is available.

How much is MFX worth (valuation)?

Valuation information for MFX is not publicly available.

Can I buy MFX stock?

MFX shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was MFX's last funding round?

MFX's most recent funding round was Grant on December 19, 2023.

Who are the main investors in MFX?

Key investors in MFX include Innovate UK, Cambridge Angels, UK Innovation & Science Seed Fund, J.B. Ugland Venture AS.

Will MFX IPO soon?

No public IPO plans have been announced for MFX.

How can I track MFX secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MFX's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStevenage
Employee Range21
Year Founded2018
Last FundingNov 19, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?